Drugs / BI 135585 XX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01652742 | Jul → Sep 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01291732 | Feb → Apr 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 135585 XX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01652742 ↗ |
| Route | Oral | “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (12.5 mg, 50 mg, 200 mg) of BI 135585 XX (Tablet)” NCT01291732 ↗ |